Meet Our CMO
PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer.
Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies. He has held positions as medical adviser, principal scientist, project manager and clinical pharmacology director. Areas of expertise span through preclinical R&D, translational sciences, and clinical development, including clinical evaluation of in-licensing opportunities.
As trained pharmacokineticist, he has routinely developed and utilised modelling and simulation techniques to facilitate studydesign and data evaluation. At present, he is based at the Clinical trials unit/Department of clinical pharmacology at Karolinska university hospital.
Meet Our CMO
PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer.
Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies. He has held positions as medical adviser, principal scientist, project manager and clinical pharmacology director. Areas of expertise span through preclinical R&D, translational sciences, and clinical development, including clinical evaluation of in-licensing opportunities.
As trained pharmacokineticist, he has routinely developed and utilised modelling and simulation techniques to facilitate studydesign and data evaluation. At present, he is based at the Clinical trials unit/Department of clinical pharmacology at Karolinska university hospital.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
